A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-tocotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.

The present invention opens to the public a method to prepare a benzopyran compound and its use for treating pulmonary fibrosis. A benzopyran compound has a structure (I): ##STR00001##
in which: R1 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R2 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R3 represents hydrogen, or C1-C4 alkyl; and n is any integer of 1-4, wherein the benzopyran compound is derived from a broth of Streptomyces xiamenensis CGMCC No. 5675 by extraction, separation and purification. The derivatives of xiamenmycin made from the present invention have a higher bioactivity to suppress the proliferation of normal human lung fibroblast, and medicinal products containing the same are useful in the treatment of pulmonary fibrosis.

The present invention aims to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure using a cationic lipid, a nucleic acid-introducing agent using a cationic lipid, and a method of achieving nucleic acid introduction by using a nucleic acid-introducing agent containing a cationic lipid. A lipid membrane structure containing a cationic lipid represented by the formula (1)

##STR00001## wherein each symbol is as defined in the DESCRIPTION, is superior in the stability in blood and tumor accumulation property. A nucleic acid-introducing agent using the cationic lipid can achieve high nucleic acid delivery efficiency of nucleic acid to be delivered into the cytoplasm.

The objective/problem addressed by the present invention is to provide a novel technique pertaining to theaflavins synthesis. The present invention pertains to: a theaflavins synthesis catalyst characterized in having a base comprising an inorganic material, and metal nanoparticles anchored to the base, said particles measuring 0.5-100 nm in diameter; and a theaflavins synthesis method in which the catalyst is used.

Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

The resist composition of the present invention contains one or more selected from compounds represented by specific formulae and resins obtained using these as monomers.

A radiation-sensitive composition contains a polymer having an acid-releasable group, and a compound (Q) represented by formula (1). In the formula (1), L.sup.1 represents an ester group, CONR.sup.3, a (thio)ether group, or a sulfonyl group. R.sup.4 represents a hydrogen atom, a substituted or unsubstituted C1 to C20 monovalent hydrocarbon group, a halogen atom, a hydroxy group, or a nitro group. R.sup.5 represents a C1 to C20 monovalent hydrocarbon group, a C1 to C20 monovalent halogenated hydrocarbon group, or a halogen atom, and optionally two R.sup.5s taken together represent an alicyclic structure together with the carbon atom(s) between the two R.sup.5s. L.sup.2 represents a single bond or a divalent linking group.

##STR00001##

A radiation-sensitive composition contains a polymer having an acid-releasable group, and a compound (Q) represented by formula (1). In the formula (1), L.sup.1 represents an ester group, CONR.sup.3, a (thio)ether group, or a sulfonyl group. R.sup.4 represents a hydrogen atom, a substituted or unsubstituted C1 to C20 monovalent hydrocarbon group, a halogen atom, a hydroxy group, or a nitro group. R.sup.5 represents a C1 to C20 monovalent hydrocarbon group, a C1 to C20 monovalent halogenated hydrocarbon group, or a halogen atom, and optionally two R.sup.5s taken together represent an alicyclic structure together with the carbon atom(s) between the two R.sup.5s. L.sup.2 represents a single bond or a divalent linking group.

##STR00001##

Novel heterocyclo compounds represented by Formula I wherein X, R1, R2, R3, R4, R5, R6 and n are as described herein are provided. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of cancer conditions in mammals including humans, including prostate, colon, bladder, melanoma, liver, breast, cervical, ovarian, esophagi, glialblastoma, pancreatic and lung cancer.

The present invention relates to the a process for total synthesis of flavonoid compounds of general formula I and isomers thereof ##STR00001##
wherein R.sub.1 and R.sub.2 is OH; R.sub.3H or ##STR00002## The present invention particularly relates to the process for preparation and separation of (2S,3S)-taxifolin-6-C--D-glucopyranoside (ulmoside A), (2R,3R)-taxifolin-6-C--D-glucopyranoside and taxifolin.